Abstract:Inflammatory bowel disease (IBD) increases the risk of colorectal cancer, and it has the potential to diminish the quality of life. Clinical and experimental evidence demonstrate protective aspects of parasitic helminth infection against IBD. However, studies on the inhibition of inflammation by helminth infection have overlooked a key determinant of health: the gut microbiota. Although infection with helminths induces alterations in the host microbiota composition, the potential influence and mechanism of helminth infections induced changes in the gut microbiota on the development of IBD has not yet been elucidated. In this study, we analyzed the intersection of helminth Trichinella spiralis and gut bacteria in the regulation of colitis and related mechanisms. T . spiralis infected mice were treated with antibiotics or cohoused with wild type mice, then challenged with dextran sodium sulfate (DSS)-colitis and disease severity, immune responses and goblet cells assessed. Gut bacteria composition was assessed by 16S rRNA sequencing and short-chain fatty acids (SCFAs) were measured. We found that protection against disease by infection with T . spiralis was abrogated by antibiotic treatment, and cohousing with T . spiralis - infected mice suppressed DSS-colitis in wild type mice. Bacterial community profiling revealed an increase in the abundance of the bacterial genus Muribaculum and unclassified_Muribaculaceae in mice with T . spiralis infection or mice cohoused with T . spiralis - infected mice. Metabolomic analysis demonstrated significantly increased propionic acid in feces from T . spiralis - infected mice. Data also showed that the gut microbiome modulated by T . spiralis exhibited enhanced goblet cell differentiation and elevated IL-10 levels in mice. These findings identify the gut microbiome as a critical component of the anti- colitic effect of T . spiralis and gives beneficial insights into the processes by which helminth alleviates colitis. IBD encompasses Crohn's Disease and Ulcerative Colitis. It affects both children and adults. Reports have highlighted the potential use of helminths or their byproducts as a possible treatment for IBD. Accumulating evidence also suggests that the gut microbiota is a key factor in modulating IBD. In this study, we revealed the protective effect of a prior infection with T . spiralis on DSS- induced colitis in mice. Specifically, T . spiralis infection reshaped the gut microbiome of mice, resulting in an increased abundance of SCFA-producing bacteria Muribaculum and unclassified_Muribaculaceae and thereby producing a larger amount of propionic acid. Furthermore, the gut microbiome modulated by T . spiralis exhibited enhanced goblet cell differentiation and elevated IL-10 levels, ultimately ameliorating experimental colitis. These findings suggest that the modulation of host microbiota during T . spiralis infection plays a crucial role in the suppression of colitis, and any intention-to-treat with helminth therapy should be based on the patient's immunological and microbiological response to the helminth.

Helminth‐derived molecules inhibit colitis‐associated colon cancer development through NF‐κB and STAT3 regulation

Helminth-derived molecules improve 5-fluorouracil treatment on experimental colon tumorigenesis

Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer

Microbiota regulation of intestinal inflammation influences colorectal cancer

Administration of intestinal mesenchymal stromal cells reduces colitis-associated cancer in C57BL/6J mice modulating the immune response and gut dysbiosis

The gut microbiota is essential for - evoked suppression of colitis

Toll‐like receptor 13‐mediated signaling protects against the development of colon cancer

Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice

Inhibition of TLR4 Signaling Impedes Tumor Growth in Colitis-Associated Colon Cancer

The gut microbiota is essential for Trichinella spiralis —Evoked suppression of colitis

Modulation of the Intestinal Microbiota Alters Colitis-Associated Colorectal Cancer Susceptibility

Suppression of Transmembrane Tumor Necrosis Factor Alpha Processing by a Specific Antibody Protects Against Colitis-Associated Cancer

Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer

Lactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model

Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer

Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer

Altered Gut Microbiota Promotes Colitis-Associated Cancer in IL-1 Receptor–Associated Kinase M–Deficient Mice

Protective Role of Fecal Microbiota Transplantation on Colitis and Colitis-Associated Colon Cancer in Mice Is Associated With Treg Cells

P099 IL-33 activates CD73-expressing cells promoting tumorigenesis during colitis-associated colorectal cancer

Tocotrienol suppresses colitis-associated cancer progression through TLR4 signaling in a mouse model of colorectal cancer